Evidence map›Paper›PMID 36655434›Full record

ArticleHaematologica2023

TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia.

Clara Bueno, Alba Martínez, Paola Alejandra Romecin, Samanta Romina Zanetti, Ricky Tirtakusuma, Eulalia Genesca, Mireia Camós, Manuel Ramírez-Orellana, Eduardo Anguita, Paola Ballerini and 3 more

Open access · goldAbstract readLetter
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Recent advances in CAR-T cell therapy for acute myeloid leukaemia.Journal of cellular and molecular medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 4 countries.

Clara BuenoJosep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; CIBER-ONC, ISCIII, Barcelona. cbueno@carrerasresearch.org.
Alba MartínezJosep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid.
Paola Alejandra RomecinJosep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid.
Samanta Romina ZanettiJosep Carreras Leukemia Research Institute, Barcelona.
Ricky TirtakusumaNewcastle University, Newcastle upon Tyne.
Eulalia GenescaJosep Carreras Leukemia Research Institute, Barcelona.
Mireia CamósHematology Laboratory, Hospital Sant Joan de Déu. Barcelona. Spain; Leukemia and other pediatric hemopathies. Developmental tumor biology group. Instiutut de Recerca Hospital Sant Joan de Déu. Barcelona.
Manuel Ramírez-OrellanaRed Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; Oncohematología. Hospital Niño Jesús. Madrid.
Eduardo AnguitaServicio de Hematología. Hospital Clínico San Carlos. IdISSC, Medicina UCM. Madrid.
Paola BalleriniPediatric Hematology. Armand Trosseau Hospital. Paris.
Franco LocatelliDepartment of Hematology and Oncology. Ospedale Bambino Gesú. Rome.
José Luis FusterSección de Oncohematología Pediátrica, Hospital Clínico Universitario Virgen de la Arrixaca and Instituto Murciano de Investigación Biosanitaria (IMIB), El Palmar, Murcia.
Pablo MenéndezJosep Carreras Leukemia Research Institute, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain; CIBER-ONC, ISCIII, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Department of Biomedicine. School of Medicine, University of Barcelona, Barcelona. pmenendez@carrerasresearch.org.
Josep Carreras Leukaemia Research Institute · ESInstituto de Salud Carlos III · ESHospital Sant Joan de Déu Barcelona · ESInstitució Catalana de Recerca i Estudis Avançats · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESInstituto Murciano de Investigación Biosanitaria · ESNewcastle University · GBRed de Investigación en Sida · ESSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaHepatitis A Virus Cellular Receptor 2HumansStem CellsHepatitis A Virus Cellular Receptor 2

Identifiers

PMID36655434
PMCPMC10388286
OpenAlexW4317479426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.